Algernon Pharmaceuticals Inc
CNSX:AGN
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
A
|
Algernon Pharmaceuticals Inc
CNSX:AGN
|
1.7m CAD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
213.5B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
188.9B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
131.1B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
114.7B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.5B EUR |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.7B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
38.2B USD |
Loading...
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
233.4B CNY |
Loading...
|
|
| JP |
|
Fujifilm Holdings Corp
TSE:4901
|
3.8T JPY |
Loading...
|
Market Distribution
Other Profitability Ratios
Algernon Pharmaceuticals Inc
Glance View
Algernon Pharmaceuticals Inc is a CA-based company operating in industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2016-02-01. Algernon Pharmaceuticals Inc. is a clinical stage pharmaceutical development company that is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough. The Company’s drug discovery approach is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Its research and development (R&D) work are carried out by the Company’s Canadian subsidiary, Nash Pharmaceuticals Inc. (Nash Pharma). The Company’s lead compound is a drug called Ifenprodil, which is being developed for idiopathic pulmonary fibrosis (IPF) and chronic cough, as well as coronavirus disease of 2019 (COVID-19).
